Drug Research
Regulations And Directive Revisions For Human Medicines
What changes are in store for the European Human Medicines Directive and Regulation when it is amended at the end of 2022?
The current European Union (EU) regulatory framework was created in 1995, and the European Medicines Agency (EMA) now...
Drug Research
Vaccines Europe Undertakes Its First Regulatory Evaluation
With 100 vaccine candidates as of July 2022, Vaccines Europe has released its first pipeline evaluation of the 15 firms that make up its membership.
The analysis uncovered a pipeline that uses a variety of new technology platforms to address...
Drug Research
By 2028, Non-Vaccine mRNA Therapy Will Earn $2 Billion
A recent analysis from GlobalData estimates that by 2028, the approval of pipeline drugs will earn over $2 billion from five marketed messenger RNA (mRNA) non-vaccine products.
The analytics firm claimed that despite the fact that there are currently no...
Drug Research
Synthetic DNA Is Tailored By AI For Future Medicine Research
Researchers at Chalmers University of Technology in Sweden have created synthetic DNA that directs the cellular creation of proteins with the aid of an AI. With the help of technology, vaccines, medications for serious illnesses, and alternative dietary proteins...
Drug Research
At $3.5M Hemgenix From CSL- uniQure The Costliest Medicine
There is a new medicine that has surpassed Bluebird Bio as the costliest in the world.
Hemgenix, a haemophilia B gene therapy developed by CSL Behring and uniQure, debuted as the first gene therapy authorised for the uncommon illness following...
Drug Research
EMA Develops A Quality Control Group To Aid Drug Development
To support innovative approaches for the development, manufacture, and quality control (QC) of medicines, along with new technologies, digitalization, novel materials, and novel devices for patients in the European Union, the European Medicines Agency (EMA) formed the Quality Innovation...
Drug Research
RVAC Medicines and A*STAR to Build Capabilities for mRNA Production in Singapore
RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company incubated by CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, and the Agency for Science, Technology and Research (A*STAR) announced the signing of a master research collaboration agreement...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read